Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?
Currently, one of the leading treatments for non-small-cell lung cancer is immunotherapy involving immune checkpoint inhibitors. These monoclonal antibodies restore the anti-tumour immune response altered by negative immune checkpoint interactions. The most commonly used immunotherapeutics in monoth...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/6/3087 |
| _version_ | 1797470883201155072 |
|---|---|
| author | Natalia Krzyżanowska Kamila Wojas-Krawczyk Janusz Milanowski Paweł Krawczyk |
| author_facet | Natalia Krzyżanowska Kamila Wojas-Krawczyk Janusz Milanowski Paweł Krawczyk |
| author_sort | Natalia Krzyżanowska |
| collection | DOAJ |
| description | Currently, one of the leading treatments for non-small-cell lung cancer is immunotherapy involving immune checkpoint inhibitors. These monoclonal antibodies restore the anti-tumour immune response altered by negative immune checkpoint interactions. The most commonly used immunotherapeutics in monotherapy are anti-PD-1 and anti-PD-L1 antibodies. The effectiveness of both groups of antibodies has been proven in many clinical trials, which have translated into positive immunotherapeutic registrations for cancer patients worldwide. These antibodies are generally well tolerated, and certain patients achieve durable responses. However, given the resistance of some patients to this form of therapy, along with its other drawbacks, such as adverse events, alternatives are constantly being sought. Specifically, new drugs targeting already known molecules are being tested, and new potential targets are being explored. The aim of this paper is to provide an overview of the latest developments in this area. |
| first_indexed | 2024-03-09T19:43:13Z |
| format | Article |
| id | doaj.art-41d93f0efcde4616bbfe5d4438643ba3 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T19:43:13Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-41d93f0efcde4616bbfe5d4438643ba32023-11-24T01:32:07ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-03-01236308710.3390/ijms23063087Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?Natalia Krzyżanowska0Kamila Wojas-Krawczyk1Janusz Milanowski2Paweł Krawczyk3Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-954 Lublin, PolandDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-954 Lublin, PolandDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-954 Lublin, PolandDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-954 Lublin, PolandCurrently, one of the leading treatments for non-small-cell lung cancer is immunotherapy involving immune checkpoint inhibitors. These monoclonal antibodies restore the anti-tumour immune response altered by negative immune checkpoint interactions. The most commonly used immunotherapeutics in monotherapy are anti-PD-1 and anti-PD-L1 antibodies. The effectiveness of both groups of antibodies has been proven in many clinical trials, which have translated into positive immunotherapeutic registrations for cancer patients worldwide. These antibodies are generally well tolerated, and certain patients achieve durable responses. However, given the resistance of some patients to this form of therapy, along with its other drawbacks, such as adverse events, alternatives are constantly being sought. Specifically, new drugs targeting already known molecules are being tested, and new potential targets are being explored. The aim of this paper is to provide an overview of the latest developments in this area.https://www.mdpi.com/1422-0067/23/6/3087non-small cell lung cancerimmunotherapyimmune checkpointsimmune checkpoint inhibitorsimmune checkpoint agonists |
| spellingShingle | Natalia Krzyżanowska Kamila Wojas-Krawczyk Janusz Milanowski Paweł Krawczyk Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules? International Journal of Molecular Sciences non-small cell lung cancer immunotherapy immune checkpoints immune checkpoint inhibitors immune checkpoint agonists |
| title | Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules? |
| title_full | Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules? |
| title_fullStr | Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules? |
| title_full_unstemmed | Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules? |
| title_short | Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules? |
| title_sort | future prospects of immunotherapy in non small cell lung cancer patients is there hope in other immune checkpoints targeting molecules |
| topic | non-small cell lung cancer immunotherapy immune checkpoints immune checkpoint inhibitors immune checkpoint agonists |
| url | https://www.mdpi.com/1422-0067/23/6/3087 |
| work_keys_str_mv | AT nataliakrzyzanowska futureprospectsofimmunotherapyinnonsmallcelllungcancerpatientsistherehopeinotherimmunecheckpointstargetingmolecules AT kamilawojaskrawczyk futureprospectsofimmunotherapyinnonsmallcelllungcancerpatientsistherehopeinotherimmunecheckpointstargetingmolecules AT januszmilanowski futureprospectsofimmunotherapyinnonsmallcelllungcancerpatientsistherehopeinotherimmunecheckpointstargetingmolecules AT pawełkrawczyk futureprospectsofimmunotherapyinnonsmallcelllungcancerpatientsistherehopeinotherimmunecheckpointstargetingmolecules |